Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07107919

Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective

Status
Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
The Affiliated Hospital of Qingdao University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I :CKD stages 1-3(eGFR ≥ 30 mL/min/1.73 m²),Group II :CKD stages 4-5(eGFR \< 30 mL/min/1.73 m²). Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.

Conditions

Interventions

TypeNameDescription
OTHER18F PET/MRTracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered. • Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds. 1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function 2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema 3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects 4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis 5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis 6. T2 Mapping (Pre Contrast):Quantify myocardial edema 7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data

Timeline

Start date
2025-07-30
Primary completion
2026-01-01
Completion
2027-06-01
First posted
2025-08-06
Last updated
2025-08-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07107919. Inclusion in this directory is not an endorsement.